secwatch.observer — SEC 8-K summary
======================================

Issuer:     Serina Therapeutics, Inc. (SER)
CIK:        0001708599
Form:       8-K
Filed at:   2023-08-30T23:59:59+00:00
Accession:  0001493152-23-030618
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.90
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AgeX Therapeutics to acquire Serina in reverse merger; Serina holders to own ~75%
--------------------------------------------------------------------------------

- AgeX stockholders expected to own ~25%, Serina holders ~75% on fully-diluted basis post-close.
- AgeX to issue 3 warrants per 5 shares held (exercise $13.20, expiring July 31, 2025) and Incentive Warrants ($18, 4-year term).
- Juvenescence (43.34% holder) commits $15M capital via warrant exercise; cancels out-of-the-money warrants.
- Post-close board of 7 directors; Steve Ledger interim CEO, Randall Moreadith CSO, Tacey Viegas COO.
- Closing conditions: reverse split to ~2.5M shares, stock price >=$12, AgeX cash >=$500k; termination fee $1M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1708599/000149315223030618/0001493152-23-030618-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1708599/000149315223030618/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-030618

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer